MYC and neoplasm: Emerging evidence indicates that perturbation of oncogenic signaling pathways may also compromise anti‐tumor immune responses, thereby contributing to resistance against molecularly targeted therapies.[35] Here we demonstrated that refractory to CDK9i might be associated with compensatory ERK‐MYC activation, recovery of pro‐oncogene transcription, infiltration of pro‐tumoral TAMs and neutrophils, and tumor angiogenesis.